OncLive TV

Reshma L. Mahtani, DO, discusses how the expansion of HER2-targeted agents has impacted the management of HER2-positive breast cancer.

Patrick I. Borgen, MD, discusses the ongoing debate of routine MRI testing in early-stage breast cancer.

Gottfried E. Konecny, MD, discusses the FDA approval of mirvetuximab soravtansine for patients with FRα-positive, platinum-resistant ovarian cancer.

Anthony V. D'Amico, MD, PhD, on the advancements in high-risk prostate cancer diagnosis and management

Henry Kuerer, MD, PhD, FACS, CMQ, on significant advancements in neoadjuvant systemic therapies in breast cancer treatment

Anna Lee, MD, MPH, discusses key takeaways from a presentation on managing head and neck cancers that was given at the 2024 ACRO Summit.

Adrianna Masters, MD, PhD, discusses pivotal events from the 2024 ACRO Summit, emphasizing the importance of mentorship in radiation oncology.

Kari Hacker, MD, PhD, discusses the proportion of HER2-expressing endometrial cancers eligible for HER2-targeted antibody-drug conjugate treatment.

Janos L. Tanyi, MD, PhD, discusses the use of pafolacianine sodium injections during cytoreductive surgery in FRα–positive ovarian cancer.

Elias Jabbour, MD, discusses the FDA approval of ponatinib plus chemotherapy for Philadelphia chromosome–positive acute lymphoblastic leukemia.

Francisco Hernandez-Ilizaliturri, MD, discusses the unique potential advantages of the radiotherapeutic iopofosine I 131 in Waldenström macroglobulinemia.

Mary-Ellen Taplin, MD, discusses strategies to mitigate health care inequities in prostate cancer.

Emmanuel Antonarakis, MD, discusses the significance of TALPRO-3, EVOPAR, and AMPLITUDE trials on the metastatic prostate cancer treatment paradigm.

Reshma L. Mahtani, DO, discusses unique challenges women may face when transitioning between different career roles within oncology.

Joshua Richter, MD, discusses ongoing or upcoming research with bispecific antibodies in relapsed/refractory multiple myeloma.

Christian Marth, MD, PhD, discusses the LEAP-001 trial of lenvatinib plus pembrolizumab vs chemotherapy in advanced or recurrent endometrial cancer.

Mansoor Raza Mirza, MD, discusses findings from part 2 of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial in primary advanced or recurrent endometrial cancer.

Judy Hayek, MD, discusses outcomes with minimally invasive vs open interval complete gross resection in patients with advanced ovarian cancer.

Leslie M. Randall, MD, MAS, discusses patient-reported outcomes from the ENGOT-cx11/GOG 3047/KEYNOTE-A18 trial in locally advanced cervical cancer.

Dimitrios Nasioudis, MD, discusses outcomes of patients with metastatic vulvar squamous cell carcinoma who underwent sentinel lymph node biopsy.

Sara Corvigno, MD, PhD, discusses the incidence of chemotherapy-related clonal hematopoiesis of indeterminate potential in patients with ovarian cancer.

I-Chia (Daniel) Liu, MD, discusses surgical and local control outcomes following short-course radiation therapy and chemotherapy for rectal cancer.

Saad J. Kenderian, MD, CHB, discusses the FDA approval of lisocabtagene maraleucel for chronic lymphocytic leukemia or small lymphocytic lymphoma.

Mary-Ellen Taplin, MD, discusses efforts to address disparities in access to, and delivery of, prostate cancer care.

James Knight, MD, discusses the potential launch of a case series of patients with brain-metastatic prostate adenocarcinoma.

Jason Efstathiou, MD, DPhil, discusses the role of tri-modality therapy in patients with muscle-invasive bladder cancer.

Vlad Gabriel Zaha, MD, PhD, discusses the risk of cardiovascular toxicity in patients with lung cancer undergoing treatment with radiation.

Raj Singh, MD, discusses radiation therapy in patients with metastatic lung cancer, highlighting the evolution of treatment within this landscape.

Idalid Franco, MD, MPH, discusses the use of radiation therapy and immunomodulatory agents in the treatment of endometrial cancer.

Jennifer K. Plichta, MD, MS, discusses key areas of interest regarding the role and optimization of genetic testing in breast cancer.